Obesity clinical trials in Pennsylvania
49 studies for Obesity are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- Geisinger Clinic, Danville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07668414A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Smithfield
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07776509AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
- UPA Ctr Weight and Eating Dis, Philadelphia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07339423A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
RecruitingPhase 3
Ages 6 to 17 · All sexes · Updated Sep 24, 2026 · NCT06672549Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
- Penn State Milton S. Hershey Medical Center, Hershey
RecruitingEarly phase 1
Ages 18 to 65 · All sexes · Updated Sep 24, 2026 · NCT06482853Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937086A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Suburban Research Associates, West Chester
- Cardiology Consultants of Philadelphia Yardley, Yardley
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07783802A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18), Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07392190A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
- University Orthopedics Center, Altoona
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07153471A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Scottdale
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07784270Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Keystone Clinical Studies, Plymouth Meeting
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07353931A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Preferred Primary Care Physicians, Uniontown
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07321886Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Heritage Valley Multispecialty Group Inc, Beaver
- Capital Area Research LLC, Camp Hill
- Abington Medical Specialists, Horsham
RecruitingPhase 3
Ages 45 to 99 · All sexes · Updated Sep 22, 2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair, Pittsburgh
- Preferred Primary Care Physicians, Uniontown
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07282600A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Philadelphia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Philadelphia
- AURORA-2 Clinical Site, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Abington Medical Specialists, Horsham
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Sep 16, 2026 · NCT07037459A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- VA Pittsburgh Healthcare System, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Frontier Clinical Research, LLC, Scottdale
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 14, 2026 · NCT06897475A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Suburban Research Associates - West Chester Office, West Chester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Philadelphia
RecruitingPhase 3Healthy volunteers welcome
Ages 18 to 79 · All sexes · Updated Sep 11, 2026 · NCT07654374AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- Clinical Research Associates of Central PA, LLC, DuBois
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07571005AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- Clinical Research Associates of Central PA, LLC, DuBois
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07571109Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
- UPA Ctr Weight and Eating Dis, Philadelphia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07770841A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Dermatology Associates of Plymouth Meeting, Plymouth Meeting
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06857942Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Capital Area Research LLC, Newport
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Sep 3, 2026 · NCT07684235A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- UPMC Child Hosp-Pittsburgh, Pittsburgh
RecruitingPhase 3
Ages 8 to 18 · All sexes · Updated Aug 31, 2026 · NCT07253285A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
- Heritage Valley Medical Group, Beaver
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT07564414Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Altoona Center for Clinical Research, Duncansville
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Aug 27, 2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Philadelphia
- Research Site, Smithfield
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07784725Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
Ages 7 to 25 · All sexes · Updated Aug 19, 2026 · NCT05082519A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Penn State Hlth Holy Spirit Med Ctr, Camp Hill
- Chambersburg Hospital, Chambersburg
- Doylestown Heath cardiology, Doylestown
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07567001Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Philadelphia
RecruitingPhase 3
Ages 18 to 79 · All sexes · Updated Aug 10, 2026 · NCT07654361Fast In-Bed Tracking (FIT) System Lifestyle Intervention is a Clinical Trial of a Bed Scale Device. Overweight Wheelchair Users Will Complete a Weight Loss Program, Half Get Scales at Baseline, Half at Month 6 Those Who Receive the Bed Scales at Baseline Are Expected to Have Increased Weight Loss
- University of Pittsburgh, Bakery Square, Department of Rehabilitation Science and Technology, Pittsburgh
Recruiting
Ages 18 and older · All sexes · Updated Jul 29, 2026 · NCT07141342Pharmacogenetics of Response to GLP1R Agonists
- Amish Research Clinic, Lancaster
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 89 · All sexes · Updated Jul 27, 2026 · NCT05071898A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
- Altoona Center for Clinical Research, Duncansville
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Jul 22, 2026 · NCT07477704An Acceptance-Based Healthy Lifestyle Intervention for Diverse Adolescents
- Drexel University, Philadelphia
RecruitingHealthy volunteers welcome
Ages 14 to 19 · Women · Updated Jul 20, 2026 · NCT06147973Weight Bias Reducation Intervention With Nursing Students Using Simulation: The BRAVE Study
- Villanova University, Villanova
Recruiting
Ages 18 to 35 · All sexes · Updated Jul 17, 2026 · NCT07334470Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- University of Pittsburgh, Pittsburgh
Recruiting
Ages 18 to 45 · Women · Updated Jun 24, 2026 · NCT05124808From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.